Evidence map›Paper›PMID 16237216›Full record

ArticleThe Journal of molecular diagnostics : JMD2005

Tumor microsatellite instability in early onset gastric cancer.

Julinor Bacani, Rhonda Zwingerman, Nando Di Nicola, Samantha Spencer, Trish Wegrynowski, Kyle Mitchell, Kazuko Hay, Mark Redston, Eric Holowaty, David Huntsman and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Finding the hot spot: identifying immune sensitive gastrointestinal tumors.Translational gastroenterology and hepatology · 2020
    Review
  9. Article
  10. World journal of gastrointestinal oncology · 2019
    Article
  11. Article
  12. Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric CancerAsian Pacific journal of cancer prevention : APJCP · 2019
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Effect of MLH1 -93G>A on gene expression in patients with colorectal cancer.Medical oncology (Northwood, London, England) · 2014
    Article
  19. Promoter methylation and immunohistochemical expression of hMLH1 and hMSH2 in sporadic colorectal cancer: a study from India.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Julinor BacaniCenter for Cancer gEnetics-Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5.
Rhonda Zwingerman
Nando Di Nicola
Samantha Spencer
Trish Wegrynowski
Kyle Mitchell
Kazuko Hay
Mark Redston
Eric Holowaty
David Huntsman
Aaron Pollett
Robert Riddell
Steven Gallinger
Mount Sinai Hospital · CABC Cancer Agency · CABrigham and Women's Hospital · USCancer Care Ontario · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) remains a leading cause of cancer mortality worldwide. Genetic factors are implicated, including DNA mismatch repair (MMR) deficiency manifested as tumor microsatellite instability (MSI). However, a standardized panel of markers and a definition of low-versus-high level MSI in GC are lacking. We examined a population-based cohort of early onset (<or=50 yrs) gastric cancer. We identified 211 cases of early onset gastric cancer in Central-East Ontario from 1989 to 1993, with archival material available for 139 cases. Testing included a six-mononucleotide marker panel and a three-MMR immunohistochemical panel. Overall, 30% (41 of 139) of GC were MSI+, with allelic shifts at one to eight markers. An unexpected discordance between the BAT-25, BAT-26, and BAT-40 markers was observed in the MSI+ cases. Six cases showing multiple loci instability (>or=3 markers MSI+/MSI-high) demonstrated MMR protein deficiency. Three novel hMLH1 mutations (two germline frameshift and one somatic nonsense) were also found. The only significant clinicopathological associations were increased tumor size in MSI+ cases (P=0.04) and Lauren histotype (P=0.006) and tumor grade (P=0.007) in MSI-high cases. Tumor size, location, depth, nodal status, and Ming subtype were significant prognostic variables. Therefore, we propose a new definition of high-level MSI based on unifying characteristics of instability of more than or equal to three of six mononucleotide markers and loss of MMR protein expression.

Indexed as

Adaptor Proteins, Signal TransducingAdultAge of OnsetCarrier ProteinsDNA-Binding ProteinsFemaleFungal ProteinsGene Expression Regulation, NeoplasticGenetic TestingGenomic InstabilityGenotypeHumansImmunohistochemistryMaleMicrosatellite RepeatsMutationAdaptor Proteins, Signal TransducingCarrier ProteinsDNA-Binding ProteinsFungal ProteinsG-T mismatch-binding proteinMLH1 protein, humanMutL Protein Homolog 1MutS Homolog 2 ProteinNuclear Proteins

Identifiers

PMID16237216
PMCPMC1888489
OpenAlexW1996860520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.